Venaxis, Inc. (NASDAQ:APPY) an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, participated in the 11th Annual Craig-Hallum Institutional Investor Conference, held on May 28, 2014, at the Minneapolis Marriott City Center. Venaxis Inc (NASDAQ:APPY) weekly performance is 12.69%. On last trading day company shares ended up $2.17. Analysts mean target price for the company is $5.67. Venaxis Inc (NASDAQ:APPY) distance from 50-day simple moving average (SMA50) is -2.33%.
Galectin Therapeutics Inc. (NASDAQ:GALT) the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced that the Company will present at the Jefferies 2014 Global Healthcare Conference, to be held June 2-5, 2014, in New York, NY. Dr. Harold H. Shlevin, Chief Operating Officer and Corporate Secretary of Galectin Therapeutics, will provide an overview of the Company’s business and recent and upcoming milestones during his live presentation. Galectin Therapeutics Inc. (NASDAQ:GALT) shares advanced 7.10% in last trading session and ended the day on $13.13. Its return on assets is -308.80%. Galectin Therapeutics Inc. (NASDAQ:GALT) quarterly performance is -28.25%.
Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced that Thomas Tulip, President and Chief Business Officer, will participate at the Jefferies 2014 Global Healthcare Conference June 2-5, 2014 at the Grand Hyatt in New York City, NY. Dr. Tulip will present a Company update on Thursday, June 5, 2014 at 1:30 PM EDT. Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) shares moved up 5.77% in last trading session and was closed at $1.65 , while trading in range of $1.56 – $1.66. Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) year to date (YTD) performance is -20.29%.
AmSurg Corp (NASDAQ:AMSG) says it will spend about $2.35 billion to buy Sheridan Healthcare in a cash and stock deal that adds physician outsourcing services to the ambulatory surgery center operator’s portfolio. Sheridan Healthcare employs more than 2,400 doctors and provides services to hospitals, ambulatory surgery centers and other locations. That includes anesthesiology, radiology and emergency medicine services. It is owned by the private equity firm Hellman & Friedman. Amsurg Corp (NASDAQ:AMSG) ended the last trading day at $45.74. Company weekly volatility is calculated as 3.04% and price to cash ratio as 31.59. Amsurg Corp (NASDAQ:AMSG) showed a positive weekly performance of 10.67%.
On May 28, Clovis Oncology, Inc. (NASDAQ:CLVS) saw a big move last session, as the company’s shares fell by over 9% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This slump shouldn’t be too much of a surprise to investors, as Clovis Oncology has seen 2 negative revisions in the past few weeks and its current year loss consensus has widened over the last 30 days. This suggests there may be more trouble down the road. Clovis Oncology Inc (NASDAQ:CLVS) weekly performance is -5.72%. On last trading day company shares ended up $51.55. Analysts mean target price for the company is $98.63. Clovis Oncology Inc (NASDAQ:CLVS) distance from 50-day simple moving average (SMA50) is -15.07%.